Skip to content
HowShorted

REATA PHARMACEUTICALS INC short interest in 2021

In 2021, REATA PHARMACEUTICALS INC's disclosed short interest ran from 9.10% of shares outstanding on 15 Jan 2021 to 11.64% on 31 Dec 2021, a change of +2.54 percentage points. The year's high was 13.21% on 30 Nov 2021 and its low 9.01% on 31 Mar 2021, averaging 10.46% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.91 days on 15 Oct 2021. Full history: REATA PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for REATA PHARMACEUTICALS INC in 2021

2021 in figures

Start of year
9.10% (15 Jan 2021)
End of year
11.64% (31 Dec 2021)
Change
+2.54 pp
High
13.21% (30 Nov 2021)
Low
9.01% (31 Mar 2021)
Average
10.46%
Highest days to cover
24.91 (15 Oct 2021)
SEC filings marked
8

Every report in 2021

REATA PHARMACEUTICALS INC short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20219.10%12.88
29 Jan 20219.31%12.73
12 Feb 20219.70%13.53
26 Feb 20219.14%13.99
15 Mar 20219.56%13.3410-K filed, results (8-K)
31 Mar 20219.01%10.07
15 Apr 20219.04%12.68
30 Apr 20219.61%10.61
14 May 202110.28%10.8310-Q filed, results (8-K)
28 May 202110.43%4.57
15 Jun 20219.64%9.91
30 Jun 202110.56%6.25
15 Jul 202110.21%13.10
30 Jul 202110.34%19.23
13 Aug 202111.52%7.7910-Q filed, results (8-K)
31 Aug 202111.11%15.99
15 Sep 202110.76%23.62
30 Sep 202110.75%24.02
15 Oct 202111.22%24.91
29 Oct 202111.39%23.16
15 Nov 202111.59%15.9510-Q filed, results (8-K)
30 Nov 202113.21%12.66
15 Dec 202111.93%1.75
31 Dec 202111.64%5.56

See also: REATA PHARMACEUTICALS INC's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.